Table 3.
Inhibitors of H3K4-specific HMTs in a clinical trial.
| Drug Name | Status | Mechanism | Cancer Type | Administration | ClinicalTrial.gov ID# |
|---|---|---|---|---|---|
| KO-539 | Phase 1/2a | Menin–MLL1 inhibitor | Relapsed or Refractory Acute Myeloid Leukemia | Oral | NCT04067336 |
| JNJ-75276617 | Phase 1 | Menin–MLL1 inhibitor | Acute Leukemias Acute Myeloid Leukemia Acute Lymphoblastic Leukemia |
Oral | NCT04811560 |
| SNDX-5613 | Phase 1/2 | Menin–MLL1 inhibitor | Acute lymphoblastic leukemia (ALL) Mixed phenotype acute leukemia (MPAL). Acute Myeloid Leukemia (AML). NPM1c AML. |
Oral | NCT04065399 |